Medtronic Rashkind Balloon Septostomy Catheter Recall Follows Death, Injury Reports

Following at least one reported death, federal health officials have announced a Class I recall for certain Medtronic catheters, due to a risk that the devices may break and separate from one another during heart procedures, increasing the risk of serious and potentially life threatening injuries.

The Medtronic catheter recall issued earlier this year has been upgraded to a Class I recall by the U.S. Food and Drug Administration (FDA) on November 3, warning of two reported injuries and one death linked to the devices breaking, separating or failing during use.

The recall impacts Medtronic Rashkind Balloon Septostomy Catheters used to enlarge an existing atrial septal defect as a treatment options for patients diagnosed with congenital heart defects, such as low blood oxygen levels.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

According to the recall upgrade notice, Medtronic has become aware of quality issues in which the devices may break, separate or fail during use, posing an increased risk of blood vessel injuries, and even death. To date, Medtronic has become aware of at least two injuries and one death related to the defect.

The recall includes an estimated 142 Rashkind Balloon Septostomy Catheters manufactured by Medtronic that are marked with the product numbers 008764, 007160, and 007161. The devices were distributed to healthcare facilities from May 28, 2018 to August 28, 2020.

Medtronic initiated the recall on August 25, and subsequently issued an Urgent Medical Device letter to all affected customers with instructions to identify and quarantine all unused devices impacted by the recall and to contact the manufacturer for instructions on how to return the products.

Following the reported injuries and death, the FDA categorized the recall and a Class I, indicating it is the most serious of its kind and the use of the devices could lead to serious and permanent injuries, or death.

As a result of the potential life-threatening consequences posed by the devices, Medtronic has announced they have stopped manufacturing and distribution of the Rashkind Balloon Septostomy Catheters.

Customers with additional questions regarding the recall are being asked to contact Medtronic Customer Service at 888-283-7688.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted 2 days ago)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 3 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 4 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.